GHSI
NASDAQGuardion Health Sciences Inc.
Website
News25/Ratings1
Latest news
25 items- SECGuardion Health Sciences Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)
- 13D/GAmendment: SEC Form SC 13G/A filed by Guardion Health Sciences Inc.SC 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)
- SECGuardion Health Sciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)
- PRGuardion Health Sciences Announces Filing of Certificate of DissolutionHOUSTON, TEXAS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that it has filed a certificate of dissolution with the Secretary of State of the State of Delaware, which became effective upon filing on October 30, 2024 (the "Effective Date"). The filing of the certificate was made pursuant to the terms of the Company's Plan of Liquidation and Dissolution (the "Plan") approved by stockholders at the Company's special meeting of stockholders held on May 31, 2024. As of October 30, 2024, Guardion has closed its stock transfer books, and record holders of shares of the Company's common stock, par value $0.001 per
- SECSEC Form 25 filed by Guardion Health Sciences Inc.25 - Guardion Health Sciences, Inc. (0001642375) (Filer)
- SECGuardion Health Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)
- PRGuardion Health Sciences Announces Adoption of Plan of Dissolution and Liquidation; Appointment of Interim President and CEOPlan includes Voluntary Delisting of Common Stock from Nasdaq and Suspension of SEC Reporting Obligations HOUSTON, TEXAS, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that it has notified the Nasdaq Stock Market ("Nasdaq") of its intent to delist its common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Capital Market. Guardion expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of the Common Stock on or about October 11, 2024 and to suspend trading of its Common Stock on the Nas
- SECGuardion Health Sciences Inc. filed SEC Form 8-K: Leadership Update8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)
- INSIDERLarge owner Radoff Bradley Louis sold $1,626,419 worth of shares (115,540 units at $14.08), decreasing direct ownership by 48% to 112,414 units (SEC Form 4)4 - Guardion Health Sciences, Inc. (0001642375) (Issuer)
- 13D/GAmendment: SEC Form SC 13G/A filed by Guardion Health Sciences Inc.SC 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)
- SECSEC Form 144 filed by Guardion Health Sciences Inc.144 - Guardion Health Sciences, Inc. (0001642375) (Subject)
- SECGuardion Health Sciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)
- PRGuardion Health Sciences Declares Cash Dividend of $5.00 Per Share of Common StockHOUSTON, TEXAS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that its Board of Directors declared a cash dividend in an amount equal to $5.00 per share of common stock held by its stockholders of record on September 9, 2024 and a payment date of September 23, 2024. Forward-Looking Statements The matters described herein may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions re
- SECGuardion Health Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)
- PRGuardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2024Guardion Also Provides an Update to Stockholders of Significant Recent Developments HOUSTON, TEXAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers science-based, clinically supported products designed for consumer ocular health, today announced its financial results for the three months and six months ended June 30, 2024, as described below. The Company also provided an update to stockholders of significant recent developments. Recent Developments: Sale of Viactiv® Brand and Business On May 31, 2024, as previously disclosed publicly, the Company completed the sale of all of t
- SECSEC Form 10-Q filed by Guardion Health Sciences Inc.10-Q - Guardion Health Sciences, Inc. (0001642375) (Filer)
- SECGuardion Health Sciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)
- SECGuardion Health Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)
- PRGuardion Health Sciences Announces Completion of Sale of its Viactiv® Brand and Business to Doctor's Best Inc. and Stockholder Approval of Plan of Liquidation and DissolutionHOUSTON, TEXAS, May 31, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced that today it closed on its Definitive Agreement to sell its Viactiv business to Doctor's Best Inc. for gross cash consideration of $17,200,000. The Company received net cash proceeds of $16,250,000 at closing, with another $225,000 retained in a third-party escrow account with U.S. Bank, NA, to be released in accordance with the terms of the transac
- SECSEC Form SCHEDULE 13G/A filed by Guardion Health Sciences Inc. (Amendment)SCHEDULE 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)
- SECSEC Form DEFA14A filed by Guardion Health Sciences Inc.DEFA14A - Guardion Health Sciences, Inc. (0001642375) (Filer)
- SECGuardion Health Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)
- NEWSGuardion Health Sciences Announces Stockholder Approval For Sale Of Viactiv Business At Special Meeting
- PRGuardion Health Sciences Announces Approval by Stockholders of Proposed Sale of Viactiv BusinessAdjourns Special Meeting to May 31, 2024 in order to Solicit Additional Proxies in Support of its Plan of Liquidation and Dissolution HOUSTON, TEXAS, May 23, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced today that its stockholders approved the previously announced sale of its Viactiv business at a special meeting (the "Meeting") held earlier today. Following this approval, the Company then adjourned the Meeting to
- NEWSGuardion Health Sciences shares are trading higher after the company announced its largest stockholder voted in favor of the proposal to approve the sale of its Viactiv brand and business and its Plan of Liquidation and Dissolution.